DongKook Pharmaceutical Cash And Equivalents vs. Return On Asset
| 086450 Stock | KRW 16,320 290.00 1.75% |
For DongKook Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DongKook Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DongKook Pharmaceutical Co utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DongKook Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DongKook Pharmaceutical Co over time as well as its relative position and ranking within its peers.
DongKook |
DongKook Pharmaceutical Return On Asset vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining DongKook Pharmaceutical's current stock value. Our valuation model uses many indicators to compare DongKook Pharmaceutical value to that of its competitors to determine the firm's financial worth. DongKook Pharmaceutical Co is number one stock in cash and equivalents category among its peers. It also is number one stock in return on asset category among its peers . The ratio of Cash And Equivalents to Return On Asset for DongKook Pharmaceutical Co is about 1,405,328,330,263 . Comparative valuation analysis is a catch-all model that can be used if you cannot value DongKook Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for DongKook Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.DongKook Return On Asset vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
DongKook Pharmaceutical |
| = | 85.44 B |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
DongKook Pharmaceutical |
| = | 0.0608 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
DongKook Return On Asset Comparison
DongKook Pharmaceutical is currently under evaluation in return on asset category among its peers.
DongKook Pharmaceutical Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in DongKook Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DongKook Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of DongKook Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of DongKook Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
DongKook Pharmaceutical Co., Ltd. provides pharmaceutical products in South Korea and internationally. DongKook Pharmaceutical Co., Ltd. was founded in 1968 and is headquartered in Seoul, South Korea. DongKook Pharm is traded on Korean Securities Dealers Automated Quotations in South Korea.
DongKook Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on DongKook Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DongKook Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DongKook Pharmaceutical's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in DongKook Pharmaceutical without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Use Investing Themes to Complement your DongKook Pharmaceutical position
In addition to having DongKook Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Real Estate ETFs Thematic Idea Now
Real Estate ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Real Estate ETFs theme has 65 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Real Estate ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in DongKook Stock
To fully project DongKook Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DongKook Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DongKook Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.